Skip to main content

Table 3 Analysis of the change in visual acuity and change in the central foveal thickness with a long follow-up of ≥ 6 months after treatment with anti-VEGF and comparison among the three agents, namely ranibizumab (RBZ), bevacizumab (BEV) and biosimilar ranibizumab (BSR)

From: Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation

nAMD long follow-up RBZ (n = 37) BEV (n = 35) BSR (n = 26) RBZ vs BEV
p value
BEV vs BSR
p value
RBZ vs BSR
p value
BCVA       
 Pre-treatment 0.60 ± 0.60 0.45 ± 0.23 0.86 ± 0.73 0.94 0.09 0.12
 Post-treatment 0.39 ± 0.35 0.41 ± 0.25 0.60 ± .60 0.32 0.40 0.14
 p value 0.001 0.20 0.02    
 Change in BCVA (95% CI) 0.21 ± 0.39 (0.01–0.32) 0.04 ± 0.26 (− 0.02 to 0.46) 0.26 ± 0.58 (− 0.21 to 0.31) 0.08 0.18 0.98
CFT       
 Pre-treatment 310.59 ± 207.62 297.34 ± 154.88 380.27 ± 285.30 0.93 0.51 0.38
 Post-treatment 174.51 ± 81.44 220.34 ± 98.02 268. ± 320.41 0.02 0.86 0.15
 p value  < 0.01 0.002 0.003    
 Change in CFT (95% CI) 136.08 ± 174.59 (− 19.97 to 138.13) 77 ± 161.74 (− 136.92 to 66.38) 112.27 ± 218.34 (− 79.27 to 126.89) 0.07 0.46 0.55
Macular edema long follow-up RBZ (n = 27) BEV (n = 31) BSR (n = 14) RBZ vs BEV
p value
BEV vs BSR
p value
RBZ vs BSR
p value
BCVA       
 Pre-treatment 0.68 ± 0.46 0.54 ± 0.3 0.51 ± 0.32 0.37 0.66 0.29
 Post-treatment 0.57 ± 0.38 0.45 ± 0.35 0.45 ± 0.43 0.16 0.72 0.21
 p value 0.12 0.07 0.07    
 Change in BCVA (95% CI) 0.12 ± 0.4 (− 0.16 to 0.22) 0.09 ± 0.32 (− 0.75 to 0.24) 0.62 ± 0.37 (0.29–0.76) 0.73 0.87 0.64
CFT       
 Pre 647.81 ± 265.48 574.48 ± 211.28 535.00 ± 213.65 0.32 0.74 0.28
 Post 421.81 ± 238.79 377.29 ± 199.99 429.35 ± 229.95 0.58 0.46 0.89
 p value 0.002 0.09 0.19    
 Change in CFT (95% CI) 226.00 ± 326.25 (− 165.32 to 169.38) 223.97 ± 306.84 (− 298.94 to 62.28) 105.64 ± 264.14 (− 70.73 to 311.45) 0.98 0.25 0.23
  1. Significant p values are in bold type